MedTrace Logo

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

NCT00256191 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2007-10-15

No results posted yet for this study

Summary

Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle.

Conditions

  • Neoplasms
  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma

Interventions

DRUG

TPI 287 Injection

Sponsors & Collaborators

  • Cortice Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Sandra Silberman, MD · Tapestry Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00256191 on ClinicalTrials.gov